IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

re Application of: Stennicke et al.

Serial No.: 10/617,500

Group Art Unit: 1646

Filed: July 11, 2003

Examiner: To be assigned

For: TF Antagonist

CERTIFICATE OF MAILING UNDER 37 CFR 1.8(a)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

I hereby certify that the attached correspondence comprising:

- 1. Supplemental Information Disclosure Statement
- 2. Form PTO-1449
- 3. Copy of References (4)

is being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on February 20, 2004

Dolly Kapadia

(name of person mailing paper)

(signature of person mailing paper)





Attorney Docket No.: 6510.200-US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of: Stennicke et al.

Application No.: 10/617,500

Group Art Unit: 1646

Filed: July 11, 2003

Examiner: To be assigned

For: TF Antagonist

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. A copy of the references is also enclosed.

The references are as follows:

- 1. WO 00/42973 A2
- 2. JP 2001213804 Translation of Abstract and Claims
- 3. Ellerby et al., Nature Medicine, Vol. 5, No. 9, pages 1032-1038 (1999)
- 4. International Search Report dated December 18, 2003

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed within three months of the filing date of a national application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, or before the mailing date of a first Office action after the filing of a request for continued examination. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Date: February 20, 2004

Len S. Smith, Reg. No. 43,139

Novo Nordisk Pharmaceuticals, Inc.

100 College Road West Princeton, NJ 08540

Respectfully submitted,

(609) 987-5800

Use the following customer number for all correspondence regarding this application.

23650

PATENT TRADEMARK OFFICE

	-						.	Shee	t 1 of
	0	(Rev. 2-32)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		Atty. Docket No. 6510.200-US		Serial No. 10/617,500		
يعا	FEB				Applicant Stennicke et al.				
夏		2 5 2004 H			Filing Date July 11, 2003		Group 1646		
Á	B	DEMOET OF	U.S. PATENT DOCUMENTS						
	-	EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING D	
	-	<u>-</u>							
	-								
i	-								
•	-	FOREIGN PATENT DOCUMENTS							
•			DOCUMENT					TRANSLAT	TION
	-		NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	YES	NO
	_		WO 00/42973 A2	7/27/00	PCT				
			JP 2001213804	8/7/01	JP			Ab-	
								stract and	
	_							Claims	
	-								
	_								
	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)								
	-	Ellerby et al., Nature Medicine, Vol. 5, No. 9, pages 1032-1038 (1999)							
		International Search Report dated December 18, 2003							

EXAMINER DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.